Combined Company Begins Trading on Nasdaq Under New Name And Ticker Symbol, (Nasdaq: NUVO)
SUNNYVALE, Calif. and CAMBRIDGE, Mass., Feb 3, 2003 /PRNewswire-FirstCall via
COMTEX/ -- Hyseq Pharmaceuticals, Inc. (Nasdaq: HYSQ) and VARIAGENICS, Inc.
(Nasdaq: VGNX) today announced that they have completed the merger of the two
companies. The combined company will be named Nuvelo, Inc. and will begin
trading on Nasdaq under the ticker symbol, NUVO, at the open of market today.
As previously announced, Dr. Ted W. Love will serve as president, CEO and board
member of Nuvelo and Dr. George Rathmann will assume the chairmanship of the new
board. The remainder of the Nuvelo board of directors will include Richard
Brewer and Mary Pendergast from the Hyseq board and Dr. Philippe Chambon, Dr.
Jean-Francois Formela and Martin Vogelbaum from the VARIAGENICS board.
"With the combination of our emerging product portfolios and strong corporate
relationships, we are confident that Nuvelo will create substantial value for
its shareholders," commented Dr. Ted W. Love, president and chief executive
officer of Nuvelo. "We are excited to leverage the strength of the new company
to continue development of our lead product candidate, alfimeprase, as well as
our other biotherapeutic and diagnostic products."
2002 Year End Results and Conference Call Information
Nuvelo will announce its fourth quarter and 2002 results on February 24, 2003
and will hold a conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time) to discuss the year end results as well as the strategy and focus of the
Nuvelo, Inc., formed by the merger of Hyseq Pharmaceuticals, Inc. and
VARIAGENICS, Inc., is engaged in the discovery and development of
biopharmaceutical and molecular diagnostic products. Nuvelo's lead product
candidate, alfimeprase, is partnered with Amgen and is currently in Phase I
clinical trials. Additional programs include cancer diagnostics and drug
discovery focused on cancer immunotherapeutics and secreted proteins.
Information about Nuvelo is available at www.nuvelo.com or by phoning
Statements contained in this press release which are not historical in nature,
are intended to be, and are hereby identified as "forward-looking statements"
for purposes of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by words such
as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and
"potential," among others. Such statements are based on our management's current
expectations and involve risks and uncertainties. Actual results and performance
could differ materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the risk that we may
not successfully integrate the VARIAGENICS business following our recent merger,
uncertainties relating to drug discovery, clinical development processes and the
development and commercialization of our molecular diagnostics technology;
changes in relationships with strategic partners and dependence upon strategic
partners for the performance of critical activities under collaborative
agreements; the impact of competitive products and technological changes;
uncertainties relating to patent protection and regulatory approval; and
uncertainties relating to our ability to obtain substantial additional funds
required for progress in drug discovery and development. These and other factors
are identified and described in more detail in Hyseq filings, and those of
VARIAGENICS, with the SEC, including without limitation our respective Annual
Reports on Form 10-K for the year ended December 31, 2001, our most recent
quarterly report on Form 10-Q, and the joint proxy statement/prospectus filed in
connection with the merger. We disclaim any intent or obligation to update these
SOURCE Hyseq Pharmaceuticals, Inc.
Nicole Estrin, Manager of Corporate Communications & IR,
Pete Garcia, Chief Financial
both of Hyseq Pharmaceuticals,
Lilian Stern, Investor Relations,
for Hyseq Pharmaceuticals, Inc.
Copyright (C) 2003 PR Newswire. All rights reserved.